TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15342830
Drug: Scopolamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine treatment
Study: 7985248
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH), dextran, or vitamin K-antagonists
Study: 2968595
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) for 12 weeks
Study: 2968595
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) + cholestyramine
Study: 2968595
Drug: Cholestyramine (with
Normalized name: cholestyramine (with sugar) ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (with simvastatin 20 mg/day)
Study: 24636808
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri probiotic preparation
Study: 23576138
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus Oxaliplatin (500 mg/m² Pemetrexed + 100 mg/m² Oxaliplatin)
Study: 23576138
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus Cisplatin (500 mg/m² Pemetrexed + 75 mg/m² Cisplatin)
Study: 18775035
Drug: Enhanced information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced information regarding life-sustaining treatment alternatives
Study: 16768770
Drug: Peritonectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonectomy with heated intraperitoneal chemotherapy
Study: 11805764
Drug: Rocuronium (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (1.0 mg/kg)
Study: 11805764
Drug: Vecuronium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.15 mg/kg)
Study: 7786375
Drug: Usual rotation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual rotation on general medicine wards (69 students)
Study: 2120178
Drug: Temafloxacin 300
Normalized name: temafloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 300 mg twice daily for ten days
Study: 2120178
Drug: Temafloxacin 600
Normalized name: temafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 600 mg twice daily for ten days
Study: 27486817
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sm-153-EDTMP and PSA-TRICOM vaccine
Study: 22520644
Drug: Letrozole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 7.5 mg daily for 3 days prior to the abortion
Study: 18819444
Drug: New high-cost
Approvals — FDA: no, EMA: no, PMDA: no
Description: New high-cost antiepileptic drugs
Study: 3521103
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine b.i.d.
Study: 3521103
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cimetidine nocte
Study: 26832653
Drug: Levofloxacin Sequential
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin Sequential Therapy (LS): lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, levofloxacin, and metronidazole for another 5 days
Study: 26832653
Drug: Levofloxacin Triple
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin Triple Therapy (LT): lansoprazole, amoxicillin, and levofloxacin for 10 days
Study: 21835900
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg in the cardiopulmonary bypass prime, 500 mg IV bolus following the final circulatory arrest, and 250 mg IV bolus 36 h after surgery)
Study: 20627877
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion (bolus dose of 1 microg kg(‐1) followed by continuous infusion of 0.5 microg kg(‐1) h(‐1))
Study: 20627877
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion (bolus dose of 2 microg kg(‐1) followed by continuous infusion of 1 microg kg(‐1) h(‐1))
Study: 16164393
Drug: TNF‐α antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α antagonists (infliximab, etanercept, adalimumab)
Study: 16164393
Drug: Screening procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Screening procedures for potential recipients of TNF‐α antagonists
Study: 11322864
Drug: Prolonged antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antiplatelet therapy
Study: 2648788
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg twice daily for 1 week, followed by 40 mg twice daily for 3 weeks)
Study: 29932581
Drug: Modified ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified ventilation mode with inversion of the respiratory cycle and high-level application of PEEP titration
Study: 21435093
Drug: 14-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day sequential therapy (esomeprazole and amoxicillin for 7 days followed by esomeprazole, clarithromycin, and metronidazole for 7 days)
Study: 17595593
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal estradiol (E2)/norethisterone acetate (NETA) patches (Estalis 25/125)
Study: 17595593
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral E2/NETA (Activelle)
Study: 9544873
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of trandolapril
Study: 9544873
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of verapamil SR
Study: 9544873
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4 mg of trandolapril and 240 mg of verapamil SR
Study: 8291491
Drug: 0.4% stannous
Normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% stannous fluoride gel (SnF2) used twice daily for 18 months
Study: 2566736
Drug: Adrenaline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline plus YAG laser therapy
Study: 30678679
Drug: Outpatient psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient psychiatric treatment for clinical mental disorder
Study: 30678679
Drug: Preventive cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive cognitive behavioural therapy for subclinical conditions
Study: 16715781
Drug: Fluoxetine tablets
Normalized name: Fluoxetine Tablets
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine tablets (test)
Study: 16715781
Drug: Fluoxetine capsules
Normalized name: Fluoxetine Capsules
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine capsules (reference)
Study: 9252131
Drug: Loperamide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (8 mg, ingested 13 and 4 hours before the meal)
Study: 8375421
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg twice daily
Study: 3752983
Drug: Aztreonam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (2 g intravenously every 6 hours for 21 doses)
Study: 31947628
Drug: Policaptil Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policaptil Gel Retard (PGR)
Study: 29707866
Drug: Dorzagliatin 75
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 75 mg BID
Study: 29707866
Drug: Dorzagliatin 75
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 75 mg QD
Study: 26984807
Drug: Topiramate administered
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate administered once a night at a dose of 2 mg/kg/day
Study: 26984807
Drug: Topiramate administered
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate administered twice a day at a dose of 4 mg/kg/day
Study: 20103825
Drug: High-quality RCTs
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality RCTs not sponsored by pharmaceutical companies
Study: 17578905
Drug: Remifentanil pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil pharmacokinetics
Study: 12029630
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg losartan
Study: 10220630
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol 5 mg x 3 plus 5 mg morphine
Study: 10220630
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo plus 5 mg morphine
Study: 7778826
Drug: Azathioprine or
Normalized name: azathioprine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine or 6-mercaptopurine therapy
Study: 7778826
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of therapy for at least 17 weeks
Study: 7778826
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of azathioprine
Study: 7778826
Drug: Increased cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased cumulative dose
Study: 27711088
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts (1 tablet per day for 3 months)
Study: 27711088
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts
Study: 27711088
Drug: Counseling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling and sexual behavioral treatment (Control Group B)
Study: 363229
Drug: Azathioprine plus
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine plus prednisone (2.5 mg/kg body weight daily)
Study: 31539169
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) - 6 weekly 2-hour group sessions
Study: 31539169
Drug: Survivorship Education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survivorship Education (SE) - 6 weekly 2-hour group sessions
Study: 25091596
Drug: Dialysate potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate potassium concentration between 1.6 and 2.5 mEq/L
Study: 21197586
Drug: high fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: high fat load (50 g fat)
Study: 16544256
Drug: ACT (Artemisinin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT (Artemisinin-based combination therapy)
Study: 10902643
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (HAART)
Study: 8317753
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia using isolated forearm technique with intravenous thiopental (3 mg/kg, 250 mg maximum) and succinylcholine (1.5 mg/kg), followed by a mixture of 50% N2O, 50% O2, and 0.5% halothane at a flow of 5 L/min and end‐tidal CO2 at 40 mm Hg. Paralysis maintained with a 0.1% succinylcholine infusion.
Study: 2427405
Drug: Anabolic steroids
Normalized name: ANABOLIC STEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroids plus phenformin
Study: 20209200
Drug: One implant
Normalized name: Testosterone Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One implant in the symphyseal area
Study: 20209200
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants in the canine positions
Study: 18665190
Drug: ACE (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE (doxorubicin 50 mg/m(2) i.v., cyclophosphamide 1 g/m(2) i.v., etoposide 120 mg/m(2) i.v. on day 1, etoposide 240 mg/m(2) orally for 2 days)
Study: 18665190
Drug: PE (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE (cisplatin 80 mg/m(2) and etoposide 120 mg/m(2) i.v. on day 1, etoposide 240 mg/m(2) orally for 2 days)
Study: 6190545
Drug: Methotrexate (MTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX), 40 mg escalated to 60 mg/m2 IV push weekly
Study: 6190545
Drug: Cisplatin (DDP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (DDP), 50 mg/m2 6 hour infusion days 1 and 8 every 4 weeks
Study: 30624856
Drug: Rolapitant tablet
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant tablet (2 × 90-mg tablets)
Study: 30624856
Drug: Rolapitant capsule
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant capsule (4 × 45-mg capsules)
Study: 30624856
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (tablet and capsule)
Study: 29878040
Drug: nab-Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-Paclitaxel plus gemcitabine (nab-P/G)
Study: 29878040
Drug: gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine plus carboplatin (G/C)
Study: 26951105
Drug: Algorithm-guided goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided goal-directed haemodynamic therapy (GDT)
Study: 8312045
Drug: Letter from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letter from general practitioner plus four information sheets at monthly intervals.
Study: 2455011
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy (group I)
Study: 2455011
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (group II)
Study: 26652592
Drug: Concurrent anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent anxiety and/or depression
Study: 23422921
Drug: Oat or
Normalized name: Therabloat Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat or barley products providing 0.3-12.1 g β-glucan
Study: 23422921
Drug: Processed foods
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Processed foods containing 4 g of β-glucan
Study: 12935409
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural blockade (TEB) with 0.5% lidocaine 3-5 ml every 2-4 hours for four weeks
Study: 12935409
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine medicine only)
Study: 3940792
Drug: Inhaled atropine
Normalized name: atropine sulfate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled atropine sulfate (0.075 mg/kg)
Study: 15649652
Drug: 450 ml
Normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 ml of black tea (acute)
Study: 15649652
Drug: 900 ml
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 ml of black tea per day (chronic)
Study: 16259812
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg oestradiol patches (Evorel) used during the pill-free interval for two cycles
Study: 16259812
Drug: Placebo used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo used during the pill-free interval for two cycles
Study: 9558519
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment at apical and radicular portions
Study: 9558519
Drug: Ultrasonic device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic device for retrograde cavity preparation
Study: 9558519
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment at apical and radicular portions instead of micro bur
Study: 7625112
Drug: DTPwHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPwHBV vaccine administered in three doses (2 months apart)
Study: 2152973
Drug: High-fiber oat
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber oat bran (87 g per day)
Study: 31740429
Drug: Home-based family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based family-based weight loss treatment
Study: 31740429
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care family-based weight loss treatment delivered in an academic medical center
Study: 28949281
Drug: Activity-based mirror
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based mirror therapy (MT)
Study: 28605294
Drug: CryJ2-LAMP DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CryJ2-LAMP DNA vaccine (4 doses of 4mg/1ml for non-sensitive subjects and 4 doses of 2mg/0.5ml for sensitive subjects)
Study: 28605294
Drug: CryJ2-LAMP DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CryJ2-LAMP DNA vaccine (1 booster dose of 2mg/0.5ml)
Study: 28605294
Drug: CryJ2-LAMP DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CryJ2-LAMP DNA vaccine
Study: 25214645
Drug: Standard Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Behavioral Treatment + Enhanced Parenting (SBT + EP)
Study: 24601050
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg for 10 days during a month for three months
Study: 21390898
Drug: Self-administered computerized
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered computerized version of TOMM
Study: 21390898
Drug: Examiner-administered booklet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Examiner-administered booklet version of TOMM
Study: 1683301
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg levonorgestrel tablets (two types)
Study: 15069173
Drug: Low-calcium dialysate
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium dialysate (LCD; calcium: 1.25 mmol/l)
Study: 15069173
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium dialysate (SCD; calcium: 1.75 mmol/l)
Study: 7939388
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with coronary heart disease, rectal cancer, and multiple sclerosis
Study: 2526993
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose omega-3 fatty acid (N3FA) supplementation (4.5 g/day)
Study: 2526993
Drug: N3FA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: N3FA supplementation (4.5 g/day)
Study: 31634905
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (4 g; n=415)
Study: 28736559
Drug: Levocarnitine injections
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine injections (1,000 mg 3 times weekly after hemodialysis)
Study: 28736559
Drug: Levocarnitine injections
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine injections
Study: 20007408
Drug: Alpha-adrenergic blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenergic blocking drug
Study: 15630469
Drug: three successive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: three successive fixed therapy interruptions (TIs) of 2, 4, and 6 weeks, with intervening resumption of therapy for 4 weeks before subsequent interruption
Study: 15630469
Drug: 40 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 weeks of continuous therapy
Study: 9222086
Drug: ET-1 (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-1 (0 (saline), 1.25, 2.5 and 5.0 ng/kg/min; 20 minutes per dose)
Study: 3819261
Drug: Dihydroergotoxine mesylate
Normalized name: Dihydroergotoxine mesylate
DrugBank: Dihydroergotoxine (DB16602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotoxine mesylate (DEM, Hydergine) at 6 mg per day, administered orally for 12 weeks
Study: 31728731
Drug: Desensitizing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agents (Vertise Flow, Universal Dentin Sealant, Clearfil Protect Bond, Flor‐Opal Varnish)
Study: 27989253
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry concentrate (60 ml dose)
Study: 24048913
Drug: Tapering group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering group (G2) - performed reduced training volume (3 sets/exercise; -22%)
Study: 23737453
Drug: Almorexant 200
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Almorexant 200 mg once daily for 10 days with warfarin 25 mg on day 5
Study: 23737453
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg on day 1
Study: 20502393
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner treatment (PDPT) with metronidazole
Study: 18443798
Drug: Early detection
Normalized name: Leader Early Detection Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early detection and treatment of amblyopia; specific intervention details not available.